Suppr超能文献

50岁及以上腹膜透析患者因暂时停止腹膜透析并使用静脉注射美罗培南治疗肠源性腹膜炎,预后得到改善。

Improved Outcome of Enteric Peritonitis in Peritoneal Dialysis Patients Aged 50 Years and Older with Temporary Discontinuation of Peritoneal Dialysis and Intravenous Meropenem.

作者信息

Abrahams Alferso C, Rüger Wim, Ter Wee Pieter M, van Ittersum Frans J, Boer Walther H

机构信息

Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands

Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands.

出版信息

Perit Dial Int. 2017 May-Jun;37(3):298-306. doi: 10.3747/pdi.2016.00147. Epub 2017 Jan 17.

Abstract

♦ BACKGROUND: Peritonitis is a major cause of morbidity, mortality, and technique failure in peritoneal dialysis (PD) patients, especially when caused by enteric microorganisms (EM). We have implemented a treatment protocol specifically aimed at improving the outcome in EM peritonitis. The adapted protocol was applied in all PD patients 50 years and older presenting with peritonitis who were considered to be at risk of EM peritonitis and involves 3 interventions: 1) temporary discontinuation of PD without removing the catheter (peritoneal rest), 2) intravenous meropenem, and 3) meropenem intracatheter as lock (Mero-PerRest protocol). ♦ METHODS: In this observational study, we compared the outcome of 203 peritonitis episodes in 71 patients treated with the Mero-PerRest protocol, with 217 episodes in 104 patients treated with a more traditional intraperitoneal gentamicin-rifampicin-based regimen. ♦ RESULTS: In EM peritonitis episodes, the Mero-PerRest protocol resulted in a higher primary cure rate (90.0% vs 65.3%, adjusted odds ratio [OR] 4.54 [95% confidence interval (CI) 1.46 - 14.15]) and better technique survival (90.0% vs 69.4%, adjusted OR 3.41 [95% CI 1.07 - 10.87]). This effect was most distinct in patients with polymicrobial EM peritonitis (cure rate 87.5% vs 34.8%, = 0.0003). Interestingly, primary cure rate (95.6% vs 84.7%, adjusted OR 3.92 [95% CI 1.37 - 11.19]) and technique survival (95.6% vs 85.6%, adjusted OR 3.60 [95% CI 1.25 - 10.32]) were also excellent in non-EM peritonitis episodes. Patient survival did not differ significantly. ♦ CONCLUSION: The poor outcome of peritonitis caused by EM in PD patients aged 50 years and older could be improved by applying a treatment protocol involving temporary discontinuation of PD without catheter removal and intravenous and intracatheter meropenem.

摘要

♦ 背景:腹膜炎是腹膜透析(PD)患者发病、死亡及技术失败的主要原因,尤其是由肠道微生物(EM)引起时。我们实施了一项专门旨在改善EM所致腹膜炎预后的治疗方案。该改良方案应用于所有年龄在50岁及以上、被认为有EM所致腹膜炎风险且出现腹膜炎的PD患者,包括3项干预措施:1)暂时停止PD但不拔除导管(腹膜休息),2)静脉注射美罗培南,3)美罗培南导管内封管(美罗培南 - 腹膜休息方案)。♦ 方法:在这项观察性研究中,我们比较了71例接受美罗培南 - 腹膜休息方案治疗的患者发生的203次腹膜炎发作的结局,与104例接受更传统的基于腹腔内庆大霉素 - 利福平方案治疗的患者发生的217次发作的结局。♦ 结果:在EM所致腹膜炎发作中,美罗培南 - 腹膜休息方案导致更高的初始治愈率(90.0%对65.3%,调整后的优势比[OR]为4.54[95%置信区间(CI)1.46 - 14.15])和更好的技术生存率(90.0%对69.4%,调整后的OR为3.41[95%CI 1.07 - 10.87])。这种效果在多重微生物EM所致腹膜炎患者中最为明显(治愈率87.5%对34.8%,P = 0.0003)。有趣的是,在非EM所致腹膜炎发作中,初始治愈率(95.6%对84.7%,调整后的OR为3.92[95%CI 1.37 - 11.19])和技术生存率(95.6%对85.6%,调整后的OR为3.60[95%CI 1.25 - 10.32])也很好。患者生存率无显著差异。♦ 结论:对于50岁及以上的PD患者,应用一项包括暂时停止PD但不拔除导管以及静脉和导管内使用美罗培南的治疗方案,可以改善由EM引起的腹膜炎的不良结局。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验